BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls

• Published in: Gynecologic oncology Vol. 151; no. 1; pp. 145 - 152
• Main Authors: Li, Ang, Xie, Rong, Zhi, Qihuan, Deng, Yixiao, Wu, Yangming, Li, Weiwei, Yang, Lu, Jiao, Zinan, Luo, Jiaqi, Zi, Yi, Sun, Gang, Zhang, Jiajia, Shi, Yujian, Liu, Jian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2018
• Subjects: BRCA gene; Case-control studies; Chinese genetic testing; Exon mutation; High-throughput nucleotide sequencing; Ovarian neoplasms; Chinese genetic testing; Case-control studies; BRCA gene; Exon mutation; Ovarian neoplasms; High-throughput nucleotide sequencing
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2018.07.024

To investigate the BRCA status in Chinese patients with ovarian cancer (OC). Though there were two large prevalence studies in Chinese OC patients, this was the first time to observe it in healthy controls. We performed BRCA mutation screening using next-generation sequencing to determine the prevalence of BRCA germline deleterious mutations in an unselected cohort of Chinese OC patients (n = 1331) versus healthy controls (n = 1763) and describe the types and spectrum of BRCA deleterious variants. Among the 1331 patients with OC, 227 (17.1%) carried deleterious variants in BRCA1 and 70 (5.3%) carried deleterious variants in BRCA2. Of 1763 control subjects, 6 (0.3%) and 2 (0.1%) had deleterious variants in BRCA1 and BRCA2. No patient carried mutations in both BRCA1 and BRCA2 simultaneously. Sixty-three novel mutations were identified, and three Chinese specific hot-spot mutations were notified as BRCA1 c.5470_5477delATTGGGCA, BRCA1 c.981_982delAT, and BRCA1 c.3770_3771delAG. Interestingly, all these high-frequency recurrent mutations were distributed on exon 10, which may also be the Chinese OC BRCA mutations' distinct characteristics. In addition, in our study, the estimated odds ratio (OR) of OC associated with BRCA1 positive variants were approximately 34.6 (95% CI, 12.5–95.7) in age group under 40 and 42.4 (95% CI, 5.9–305.2) in group older than 50 in the Chinese population, respectively. We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management. •22.4% (17.1% BRCA1, 5.3% BRCA2) OC patients and 0.4% (0.3 BRCA1, 0.1% BRCA2) controls carried deleterious variants in Chinese.•The dense cluster of mutations in BRCA1 exon10 indicated that hypermutation was a characteristic of Chinese OC patients.•The estimated odds ratio (OR) of OC associated with BRCA1 positive variants was 34.6 (95% CI, 12.5–95.7) in age < 40 group.•The OR was 42.4 (95% CI, 5.9–305.2) in age ≥ 50 group.